Blocking BET bromodomains with JQ1(+) has exhibited high preclinical efficacy in a growing number of malignancies (Zuber et al., 2011, Delmore et al., 2011, Brown et al., 2014, Anand et al., 2013). This evidence concerns the gene DNER and cancer.